Indivior Pharmaceuticals, Inc. clinical trials
The registry lists 54 studies whose lead sponsor is Indivior Pharmaceuticals, Inc. or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 5, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 54studies on the registry
- 0open to participants now
What it is testing
The drugs Indivior Pharmaceuticals, Inc.’s studies test, most studies first; none is open now — 9 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 54 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 508
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 4 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Indivior Pharmaceuticals, Inc.
- Indivior Inc.51 studiesSame company
Something wrong?
- Opiant Pharmaceuticals Inc3 studies →Acquired — became part of Indivior Pharmaceuticals, Inc., Mar 2, 2023 · source ↗
Something wrong?
Focus areas
Conditions Indivior Pharmaceuticals, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 →
- SUBLOCADE Long-term OutcomesCompletedNCT05860959
Sponsor listed in the registry: Indivior Inc.
- INDV-6001 Multiple-Dose Pharmacokinetic StudyCompletedNCT06576843Phase 2
Sponsor listed in the registry: Indivior Inc.
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersCompletedNCT04995029Phase 4
Sponsor listed in the registry: Indivior Inc.
- Evaluating the SUBLOCADE Treatment Exit StrategyCompletedNCT05878210
Sponsor listed in the registry: Indivior Inc.
- Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderCompletedNCT06384157Phase 2
Sponsor listed in the registry: Indivior Inc.
- Pharmacodynamic Evaluation of Intranasal NalmefeneCompletedNCT04828005Phase 1
Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.
- SUBLOCADE Rapid Initiation StudyCompletedNCT03993392Phase 4
Sponsor listed in the registry: Indivior Inc.
- SUBLOCADE Rapid Initiation Extension StudyCompletedNCT04060654Phase 4
Sponsor listed in the registry: Indivior Inc.
- Buprenorphine-Fentanyl Interaction StudyCompletedNCT03747341Phase 1
Sponsor listed in the registry: Indivior Inc.
- Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male ParticipantsCompletedNCT05974046Phase 1
Sponsor listed in the registry: Indivior Inc.
- Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsCompletedNCT05704543Phase 4
Sponsor listed in the registry: Indivior Inc.
- Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use DisorderCompletedNCT04976855Phase 1
Sponsor listed in the registry: Indivior Inc.
- Pharmacokinetic Evaluation of Intranasal NalmefeneCompletedNCT04759768Phase 1
Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.
- Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing RegimensCompletedNCT05219669Phase 1
Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.
- Study of Potential CYP3A4 Induction by INDV-2000 in Healthy AdultsCompletedNCT05694533Phase 1
Sponsor listed in the registry: Indivior Inc.
- INDV-2000 First in HumanCompletedNCT04413552Phase 1
Sponsor listed in the registry: Indivior Inc.
- Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)CompletedNCT01075971Phase 2
Sponsor listed in the registry: Indivior Inc.
- Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)CompletedNCT00684073Phase 4
Sponsor listed in the registry: Indivior Inc.
- Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)CompletedNCT00723697
Sponsor listed in the registry: Indivior Inc.
- Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)CompletedNCT00756353
Sponsor listed in the registry: Indivior Inc.
- An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long TermTerminatedNCT04577144
Sponsor listed in the registry: Indivior Inc.
- Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral RisperidoneCompletedNCT03978832Phase 4
Sponsor listed in the registry: Indivior Inc.
- Evaluation of Long-term Buprenorphine Plasma ExposureCompletedNCT03752528
Sponsor listed in the registry: Indivior Inc.
- An Observational Study of Environmental and SocioEconomic Factors in Opioid RecoveryCompletedNCT03604861
Sponsor listed in the registry: Indivior Inc.
- Study of a Novel Subcutaneous Depot Formulation of BuprenorphineCompletedNCT03715634Phase 1
Sponsor listed in the registry: Indivior Inc.
- Open-Label Treatment Extension StudyCompletedNCT02896296Phase 3
Sponsor listed in the registry: Indivior Inc.
- Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia PatientsCompletedNCT02109562Phase 3
Sponsor listed in the registry: Indivior Inc.
- Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/EfficacyCompletedNCT01677377Phase 2
Sponsor listed in the registry: Indivior Inc.
- Long Term Study of RBP 7000 in the Treatment of Subjects With SchizophreniaCompletedNCT02203838Phase 3
Sponsor listed in the registry: Indivior Inc.
- Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid DisorderCompletedNCT02044094Phase 2
Sponsor listed in the registry: Indivior Inc.
- Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use DisorderCompletedNCT02510014Phase 3
Sponsor listed in the registry: Indivior Inc.
- Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent SubjectsCompletedNCT01738503Phase 2
Sponsor listed in the registry: Indivior Inc.
- Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of BuprenorphineCompletedNCT02357901Phase 3
Sponsor listed in the registry: Indivior Inc.
- A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy VolunteersCompletedNCT03058237Phase 1
Sponsor listed in the registry: Indivior Inc.
- Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/NaloxoneCompletedNCT00637000Phase 2
Sponsor listed in the registry: Indivior Inc.
- Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent PopulationCompletedNCT02038790Phase 4
Sponsor listed in the registry: Indivior Inc.
- Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)CompletedNCT00725608
Sponsor listed in the registry: Indivior Inc.
- Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use DisorderCompletedNCT02559973Phase 1
Sponsor listed in the registry: Indivior Inc.
- PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With SchizophreniaCompletedNCT02687984Phase 1
Sponsor listed in the registry: Indivior Inc.
- A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use DisorderCompletedNCT02511886Phase 2
Sponsor listed in the registry: Indivior Inc.
- Transfer of Subjects From Subutex/Suboxone to RBP-6300CompletedNCT01582347Phase 2
Sponsor listed in the registry: Indivior Inc.
- Single Ascending Dose Study of RBP-6000CompletedNCT03002961Phase 1
Sponsor listed in the registry: Indivior Inc.
- Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired SubjectsCompletedNCT01846455Phase 4
Sponsor listed in the registry: Indivior Inc.
- A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)CompletedNCT00605033Phase 4
Sponsor listed in the registry: Indivior Inc.
- A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine AbuseCompletedNCT01846481Phase 2
Sponsor listed in the registry: Indivior Inc.
- A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux DiseaseCompletedNCT00838396Phase 2
Sponsor listed in the registry: Indivior Inc.
- Single Ascending Dose Study of RBP-7000CompletedNCT02768649Phase 1
Sponsor listed in the registry: Indivior Inc.
- Single-dose, Study of RBP-6000 in Opioid Dependent IndividualsCompletedNCT02765867Phase 1
Sponsor listed in the registry: Indivior Inc.
- First in Man Study of Safety, Tolerability and PK Profile of RBP-7000CompletedNCT02765555Phase 1
Sponsor listed in the registry: Indivior Inc.
- Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")CompletedNCT00955162Phase 4
Sponsor listed in the registry: Indivior Inc.